[RESEARCH BLOG] · 2026-08-21
Hims & Hers Health, Inc. (HIMS) – BUY Signal Amid Recovery Regime and Rising Share Momentum
By Pierre Brunelle · Founder & Research Lead
Lopsided upside: Hims & Hers closed at $33.78, up 6.03 % on 2026‑08‑21 (Friday, US session). The LOPJLB platform now flags a BUY directional signal with a perfect Score 5 in a RECOVERY market regime, positioning the stock as a “Growth Compounder” archetype.
News / Catalysts
-
Kaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violations – filed a formal alert on 2026‑08‑21, warning investors that Hims & Hers Health, Inc. is under investigation for potential securities‑law violations. The notice, posted on Newsfile, urges shareholders to monitor the unfolding inquiry and consider contacting the firm for further details.
-
HIMS INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm – released a parallel advisory later the same day, encouraging HIMS investors to reach out to the firm for guidance. The press release, distributed via GlobeNewswire, emphasizes that the investigation could have material implications for the company’s governance and disclosure practices.
-
Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm – announced an investigation on 2026‑08‑21, this time on behalf of HIMS stockholders. The filing, again reported by GlobeNewswire, focuses on alleged breaches of fiduciary duty by the board and calls for a thorough review of corporate oversight.
-
HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally? – highlighted on 2026‑08‑21 that HIMS shares have more than doubled over the prior six months, attributing the rally to aggressive subscriber acquisition, expanded product lines, and the rollout of a new tele‑dermatology platform. The analysis notes that the stock’s price momentum is outpacing earnings growth, creating a valuation disconnect that some contrarians find appealing.
-
Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access – reported on 2026‑08‑19 that Hims & Hers rejected a set of privacy‑related allegations while pledging to broaden patient access to its digital health services. The company’s statement stressed compliance with HIPAA standards and announced upcoming enhancements to its data‑security infrastructure, aiming to reassure both regulators and consumers.
Fundamentals and Valuation
Hims & Hers Health, Inc. (NYSE: HIMS) operates a fully digital health platform that connects consumers with licensed clinicians for prescription and wellness services. The firm’s financial profile reflects a rapid growth trajectory tempered by ongoing profitability challenges.
Valuation snapshot (as of the latest filing)
| Metric | Value |
|---|---|
| P/E (TTM) | ‑55.38 |
| Forward P/E | 105.5 |
| EV/EBITDA | ‑110.9 |
| Gross margin | 64.68 % |
| Operating margin | ‑3.59 % |
| Net margin | ‑5.51 % |
| ROE | ‑32.03 % |
| ROA | ‑3.91 % |
| PEG | 1.99 |
| Analyst target price | $28.36 (Hold) |
The trailing P/E of –55.38 underscores that earnings are still negative on a GAAP basis, while the forward P/E of 105.5 signals that analysts expect earnings to turn modestly positive but remain far below the current price. The EV/EBITDA of –110.9 mirrors the same earnings deficit, reinforcing the notion that the market is pricing in future profitability rather than present cash generation.
Revenue growth has been the engine of the company’s valuation. From $148.8 M in 2020 to $2.35 B in 2025, HIMS has compounded revenue at an approximate CAGR of 70 % over the six‑year span. The most recent twelve‑month period (2025) recorded $2.35 B, a 28.04 % year‑over‑year increase, reflecting continued success in expanding its subscription‑based medication and tele‑health offerings.
Margins have shown a gradual improvement. Gross margin climbed from 73.58 % in 2020 to 79.45 % in 2024, before a slight dip to 73.84 % in 2025 as the firm invested heavily in new product lines. Operating margin, historically deep in the red (‑42.31 % in 2021), turned positive in 2024 at 4.19 % and modestly improved to 4.50 % in 2025, indicating that the company is beginning to leverage scale to offset operating expenses. Net margin followed a similar trajectory, moving from ‑12.18 % in 2020 to 8.54 % in 2024, before settling at 5.47 % in 2025.
Earnings per share (EPS) turned positive only in 2024, reaching $0.58, and remained essentially flat at $0.57 in 2025. The ‑173.4 % EPS growth figure in the current fundamentals reflects the swing from a negative EPS base in prior years to modest profitability now. Free cash flow (FCF) turned positive in 2023 ($46.99 M) and grew to $73.96 M in 2025, delivering a FCF yield of 1.19 %—still modest but a marked improvement over the negative cash‑flow years of 2020‑2022.
Balance‑sheet considerations remain a point of caution. The debt‑to‑equity ratio of 477.1 signals a heavily leveraged capital structure, while an interest coverage ratio of 999.0 (likely a data artifact) suggests that interest expense is currently negligible relative to earnings, perhaps due to low‑interest financing or accounting treatment. The Altman Z‑score of 1.85 places HIMS in the “gray zone” between safe and distress, reinforcing the need for investors to monitor liquidity trends.
Overall, the company’s growth score of 50.00 and GARP score of 44.20 reflect a strong top‑line trajectory paired with a valuation that, while high, is not yet out of reach for a growth‑oriented investor. The quality score of 35.17 is modest, driven largely by the negative ROE and high leverage, but the upward trend in margins and cash generation suggests a potential shift toward higher quality in the coming years.
ETF Ownership
Hims & Hers is held across a broad set of thematic ETFs that focus on health‑tech, digital health, and emerging consumer‑care trends. Concentrated ownership by a few large funds can amplify price moves when those ETFs rebalance or adjust sector allocations.
| ETF (Ticker) | Weight in HIMS |
|---|---|
| EDOC | 5.74 % |
| MEME | 5.25 % |
| THNR | 4.52 % |
| HEAL | 4.02 % |
| FDHT | 2.60 % |
| EKG | 2.42 % |
| IBUY | 2.36 % |
| XHS | 1.57 % |
| PTH | 1.50 % |
| BUZZ | 1.45 % |
| RFG | 0.95 % |
| IHF | 0.84 % |
The two largest holders, EDOC and MEME, together account for over 11 % of the float, indicating that any sector‑wide reallocation within these funds could materially affect HIMS’s share price. The diversified exposure across twelve ETFs also provides a degree of liquidity support, especially during periods of heightened market volatility.
LOPJLB Signal Read
The LOPJLB engine currently issues a BUY directional signal for HIMS, anchored in a RECOVERY market regime that has persisted for three days. The composite PERF score of 46.70 and FUND quality score of 35.17 place the stock in the upper‑mid tier of the platform’s ranking system.
- Value score: 6.00 (low) – the market is pricing the stock at a premium relative to traditional value metrics.
- Growth score: 50.00 – reflects the strong top‑line expansion and improving margins.
- GARP score: 44.20 – indicates a blend of growth and reasonable price expectations.
- Quality score: 35.17 – modest, driven by high leverage and negative ROE, but trending upward as cash flow improves.
The Growth Compounder archetype aligns with HIMS’s narrative: a high‑growth digital health platform that is beginning to translate subscriber acquisition into earnings and free cash flow. The platform’s EMA bullish crossover (5‑day EMA above 20‑day EMA) and a stochastic K of 97.5 further reinforce the technical backdrop of upward momentum, though those overlays are visualized on the interactive chart rather than detailed here.
Investors interested in the full overlay suite—including proprietary signals—should explore the interactive chart on the HIMS stock page. For a deeper dive into the methodology that drives these signals, visit the LOPJLB methodology page.
Closing Thoughts & Resources
Hims & Hers Health sits at a crossroads of rapid revenue expansion, improving operational efficiency, and a series of high‑profile investigations that could introduce short‑term volatility. The BUY signal from LOPJLB, coupled with a RECOVERY market regime and a Growth Compounder archetype, suggests that the upside potential may outweigh the near‑term risk for investors comfortable with a growth‑oriented, high‑leverage profile.
For the latest price action, detailed valuation tables, and the full suite of technical overlays, visit the dedicated stock page: https://www.lopjlb.com/stock/HIMS. If an earnings call transcript becomes available, the corresponding analysis will be posted at https://www.lopjlb.com/stock/HIMS/earnings.md. To screen for similar opportunities across the market, explore the LOPJLB screener at https://www.lopjlb.com/screener.
The information provided herein is for research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.